|1.||Khazipov, Rustem: 2 articles (01/2007 - 10/2005)|
|2.||Isaev, Dmytro: 2 articles (01/2007 - 10/2005)|
|3.||Holmes, Gregory L: 2 articles (01/2007 - 10/2005)|
|4.||Isaeva, Elena: 2 articles (01/2007 - 10/2005)|
|5.||Sastry, B R: 1 article (10/2015)|
|6.||Tadavarty, R: 1 article (10/2015)|
|7.||Rajput, P S: 1 article (10/2015)|
|8.||Soja, P J: 1 article (10/2015)|
|9.||Hwang, J: 1 article (10/2015)|
|10.||Kumar, U: 1 article (10/2015)|
01/01/2007 - "Diazepam and isoguvacine completely prevented seizures induced by 10 mM [K(+)](o). "
11/01/1990 - "6. While the potentiation by FG 8205 of the response to isoguvacine in the rat hippocampal slice and the anxiolytic-like effects of the compound in both rats and primates were reversed by the benzodiazepine receptor antagonist, flumazenil, high doses of the antagonist were able only marginally to block the protective effects of FG 8205 against seizures induced by PTZ in the mouse. "
08/01/2011 - "Both the cannabinoid receptor agonist WIN55212-2 (10, 30, 50 and 100 μg/rat) and the GABA-A receptor agonist isoguvacine (IGN; 10, 30 and 50 μg/rat) significantly increased the latency of seizure occurrence. "
10/01/2005 - "Co-infusion of the GABA(A) receptor agonist isoguvacine or the GABA(A)-positive allosteric modulator diazepam completely prevented high-K(+)/low Mg(2+)-induced seizures. "
07/01/1983 - "This seizure activity was prevented, attenuated or reversed by intracerebroventricular administration of 20 microliter of GABA (1 mumol), muscimol (0.025 mumol), trans-4-aminocrotonic acid (0.25 mumol), isoguvacine (0.25 mumol) or THIP (0.25 mumol), but not by biogenic amines. "
|2.||Prostatic Neoplasms (Prostate Cancer)
01/01/2008 - "A GABAa agonist isoguvacine, at doses between 5-50 microg/ml (31-310 microM), stimulated the proliferation of all four human prostate cancer cell lines, tested. "
03/05/2014 - "Using androgen-insensitive bone metastasis PC-3 cells and androgen-sensitive lymph node metastasis LNCaP cells derived from human prostate cancer (PCa) patients, we demonstrated that γ-aminobutyric acid A receptor (GABA(A)R) ligand (GABA) and agonist (isoguvacine) stimulate cell proliferation, enhance EGF family members expression, and activate EGFR and a downstream signaling molecule, Src, in both PC-3 and LNCaP cells. "
10/08/2015 - "TPMPA, a GABA-C receptor antagonist blocked the effects of CACA but not isoguvacine indicating that GABA-C receptors are involved in regulating pain. "
08/01/1997 - "Pretreatment with the GABA(A) receptor agonists, muscimol (0.3 microg) or isoguvacine (10 or 30 microg i.t.), significantly decreased the number of flinches in phase 1 and phase 2, but produced only a marginal decrease in the weighted pain score at the highest doses. "
08/20/1993 - "The GABAA antagonist SR 95531 was judged unsuitable because it caused only a modest 1.7-fold rightward shift in the dose-effect relationship of isoguvacine at doses that did not produce allodynia. "
08/20/1993 - "bicuculline caused a 3.4-fold rightward shift in the dose-effect relationship of the i.t.-administered GABAA agonist, isoguvacine, without producing allodynia or alterations in nociceptive threshold. "
05/01/2002 - "Isoguvacine and baclofen each reversed tactile allodynia and thermal hyperalgesia produced by spinal nerve ligation. "
11/01/1995 - "Anoxic effects on slope conductances and reversal potential of isoguvacine responses and monosynaptic IPSCA coincided, suggesting that evoked transmitter release from GABAergic terminals was not affected by anoxia. "
11/01/1995 - "Responses to pressure-applied isoguvacine, a GABAA receptor agonist, were reversibly depressed by anoxia, again because of a positive shift in reversal potential and decrease in conductance. "
12/01/1993 - "Responses to pressure application of isoguvacine (GABAA agonist) were also not affected by anoxia.(ABSTRACT TRUNCATED AT 250 WORDS)"
|1.||GABA-A Receptors (GABA(A) Receptor)
|4.||GABA-A Receptor Agonists
|6.||gamma-Aminobutyric Acid (GABA)
|8.||4,5,6,7- tetrahydroisoxazolo(5,4- c)pyridin- 3- ol (THIP)
|9.||Cannabinoid Receptors (Cannabinoid Receptor)
|10.||Epidermal Growth Factor (EGF)